French biotechnology company Abolis Biotechnologies has launched a platform designed to shorten the discovery cycle for microbial-derived cosmetic ingredients, an area where multi-omics data has historically been difficult to interpret for product development teams.

The Microbial Intelligence Explorer (MINE), announced in a company statement, supports manufacturers and R&D teams in understanding, interpreting and acting on complex microbial systems. It connects microbial and multi-omics data — a combined dataset merging two or more biological data layers — with experimental and industrial insight to support product innovation, process development and scale-up.

Abolis claims microbial systems hold significant potential for industries seeking new approaches to product performance, supply chain resilience and more sustainable production. These are manufacturer claims; the platform is a new release and the company has not yet published independent trial data on its performance.

Why does microbial ingredient discovery stall?

According to Abolis, the bottleneck for manufacturers and R&D teams is not identifying what microbes can do. The real challenge sits one level deeper: understanding which biological mechanisms and parameters are relevant at the metabolic level, and which development routes warrant further investigation.

Sylvia Julien, General Manager of the MINE Business Unit, framed the problem in terms of signal versus noise. "The challenge in microbial biotechnologies lies in the difficulty of integrating the various pieces of information and, therefore, to know which signals matter and which hypotheses deserve further testing for product development," she said.

"MINE gives teams a clearer way to navigate that complexity, helping them focus experimental work on the questions most likely to move a programme forward," Julien added.

How was the platform built?

MINE brings together three components: genomic exploration, multi-omics analysis and experimental interpretation. The platform helps teams examine how individual strains contribute to producing molecules of interest and understand interactions within more complex microbial systems.

The tool has a traceable technical lineage. It is based on Microbiome Studio, a machine learning-enabled analytical platform created out of the Metapath project — an industrial programme supported by the French government. Abolis originally built Microbiome Studio for its own microbial biotechnology programmes, then refined it through industrial collaborations before developing it into MINE for external R&D and open innovation teams.

That external orientation carries a practical consequence for cosmetics manufacturers: MINE makes microbial data accessible to R&D and open innovation teams without requiring every decision maker to be an omics or bioinformatics specialist.

What does the launch mean for Abolis and its partners?

Cyrille Pauthenier, co-founder and CEO of Abolis Biotechnologies, positioned the release as the commercial culmination of the company's accumulated expertise, which spans industrial biotechnology, microbiology, microbial fermentation, metabolism, robotics and intellectual property strategy.

"MINE software release marks the point at which more than a decade of microbial biotechnology, data and industrial experience of Abolis becomes a platform to boost partners' research and our own research," Pauthenier said.

"It strengthens Abolis' ability to support decisions before, during and beyond experimentation, connecting biological evidence with the realities of validation, process development and scale-up," he continued. "For our partners, that means a clearer route from microbial potential to an industrially relevant programme."

A wider industrial strategy

The launch reflects Abolis' broader focus on making microbial biotechnology more industrially available. Founded in 2014, the company operates at the intersection of fermentation science, metabolic engineering and IP strategy, and the MINE release externalises capabilities it previously kept in-house.

For cosmetic ingredient developers, the platform arrives as the industry increasingly looks to microbial fermentation as a route to novel actives with more resilient supply chains and lower environmental footprints than traditional extraction or chemical synthesis.

Whether MINE shortens time-to-market for microbial-derived cosmetic ingredients will depend on early partner results. Abolis' stated roadmap — supporting decisions before, during and beyond experimentation — suggests the company intends the platform to function across the full development chain, from strain screening through validation, process development and scale-up.